On January 21, 2026, Smith J. Jefferson, serving as Chief Research Officer for Precision Biosciences Inc (NASDAQ:DTIL), sold 10,200 shares of the company's common stock at $4.03 per share. This transaction amounted to approximately $41,106 in total proceeds.
Adding to his equity position, Jefferson received 29,166 shares through the vesting of Restricted Stock Units on January 20 and 21, 2026. These acquisitions reflect standard compensation practices aligning management interests with shareholder value.
Meanwhile, Precision Biosciences has announced continued advancements in its gene editing initiatives. The firm's Phase 1/2a ELIMINATE-B clinical trial, targeting chronic hepatitis B, is actively progressing, demonstrating early promise. Additionally, the company anticipates receiving regulatory approval for its Duchenne muscular dystrophy program during the first quarter of 2026, signaling potential pipeline expansion.
Financially, Precision Biosciences reported approximately $137 million in cash, cash equivalents, and restricted cash as of December 31, 2025. This funding is expected to support the company's data-driven milestones through 2028, reflecting prudent financial planning and resource allocation.
Further bolstering its balance sheet, the company recently completed an underwritten offering raising nearly $75 million by selling 10,815,000 shares of common stock along with attached warrants. This capital injection aims to fund ongoing research and development efforts.
Promising early-stage clinical data were also disclosed, highlighting results from the Phase 1 ELIMINATE-B study. The trial showed dose-dependent antiviral activity in all nine patients treated in the initial cohorts, underscoring the potential therapeutic benefits of Precision Biosciences’ gene editing approach for chronic Hepatitis B.
Collectively, these developments indicate the company’s sustained commitment to advancing innovative therapies within the gene editing sector, with financial strategies aligned to support long-term clinical progress.